Product category:
Pharmaceutical Processing News
News Release from: Amersin Life Sciences
Edited by the Processingtalk Editorial
Team on 13 July 2004
Injection production facilities
certificated
HBBenda JV has been granted an operating license for pharmaceutical research and development: initial production has commenced and they have been granted GMP certification to the latest standards
Hubei Pharmaceutical Group announced today that its new joint venture, a 60% controlling interest in Hubei Tongji Benda Ebei Pharmaceutical Co located in Guangshui City, Hubei Province, China is operational HBBenda JV has been granted an operating license for pharmaceutical research, development, production and distribution as a Sino-American Joint Venture Corporation
This article was originally published on Processingtalk on 9 Jul 2003 at 8.00am (UK)
Related stories
Robot army for Land Rover
ABB, the global power and automation technologies group, announced today that it has won an order from Ford Premier Automotive Group to supply 186 industrial robots to Land Rover
ABB creates new Nationwide instrumentation network
A new comprehensive instrumentation supply and service network has been created by ABB to serve customers throughout the UK: the Instrumentation Alliance comprises five carefully selected partners
Initial production has commenced on the production lines acquired as part of the vend-in by the minority partner of its operating dosage division.
They are the largest small format injection production facilities in Central China and were granted GMP certification to the latest standards following upgrades and modernisation completed in the 4th quarter last year.
A total of 79 generic and high-tech products are sold domestically in over 20 provinces, cities and autonomous regions.
Products are also exported to other countries in Southeast Asia.
Work on a new tablet and capsule production facility is well underway.
It is expected that it will be completed in the third quarter and operational as soon as GMP certification and licenses are issued in the third or fourth quarter paving the way for the introduction of several new strategic products.
An independent audit team has returned to North America.
Additional details will be filed with audited statements for the new acquisition within several weeks.
Hubei Pharmaceutical Group is engaged in the acquisition of pharmaceutical development, production and distribution facilities in China.
The addition of HBBendaJV marks a strategic move into the Biotech field, expands the distribution network into regions not previously serviced and is expected to contribute significantly to revenue and profitability in its first year of operation.
• Amersin Life Sciences: contact details and other news
• Email this article to a colleague
• Register for the free Processingtalk email newsletter
• Processingtalk Home Page
Search the Pro-Talk network of sites
